Dr. Philippe Pouletty, MD, is Chairman at Deinove SA, a Managing Director & Director at Truffle Capital SAS, Chairman at Splicos SAS, a Director at Plasmaprime SAS, a Director at Pharnext SAS, and Chairman at Theradiag SA.
He is on the Board of Directors at Carmat SA, Neovacs SA, Vexim SA, Innate Pharma SA, Truffle Capital SAS, Symetis SA, Immune Targeting Systems (ITS) Ltd., Theraclion SA, Wittycell SAS, Plasmaprime SAS, Pharnext SAS, and France Biotech Association.
Dr. Pouletty was previously employed as Chairman by SangStat Medical Corp., Founder by Sangstat Pharmaceuticals Corp., a Manager by Nakostech SARL, a Member by Conseil Stratégique pour l'Innovation, a Member by Strategic Council on Business Attractiveness, a Member-Supervisory Board by Cytomics Pharmaceuticals SA, and Vice Chairman by EuropaBio.
He also served on the board at ConjuChem Biotechnologies, Inc., MyoPowers Medical Technologies SA, and Drugabuse Sciences, Inc.
He received his doctorate degree from Université Pierre et Marie Curie.